Skip to main content
. 2022 Dec 9;12(6):6980–6993. doi: 10.1002/cam4.5495

FIGURE 3.

FIGURE 3

Cumulative overall survival curves by neo‐GPS score in patient subgroups. (A) Patients with a Child–Pugh score of 5. The cumulative overall survival rates of patients with a neo‐GPS score of 0 at 3, 6, and 12 months are 98.3%, 96.5%, and 90.7%, respectively (solid line). In patients with a neo‐GPS score of ≥1, the cumulative overall survival rates are 97.5%, 90.5%, and 71.2% at 3, 6, and 12 months, respectively (dotted line) (p = 0.001, log‐rank test). (B) Patients with NLR <3. The cumulative overall survival rates of patients with a neo‐GPS score of 0 at 3, 6, and 12 months are 100.0%, 97.1%, and 89.6%, respectively (solid line). In patients with a neo‐GPS score of ≥1, the cumulative overall survival rates are 97.5%, 90.2%, and 69.6% at 3, 6, and 12 months, respectively (dotted line) (p = 0.001, log‐rank test). (C) Patients with α‐fetoprotein < 100 ng/ml. The cumulative overall survival rates of patients with a neo‐GPS score of 0 at 3, 6, and 12 months are 98.8%, 97.4%, and 94.3%, respectively (solid line). In patients with a neo‐GPS score of ≥1, the cumulative overall survival rates are 98.7%, 89.0%, and 69.1% at 3, 6, and 12 months, respectively (dotted line) (p < 0.001, log‐rank test). GPS, Glasgow prognostic score; NLR, neutrophil‐to‐lymphocyte ratio.